Keytruda
E468955
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| pembrolizumab | 1 |
Statements (55)
| Predicate | Object |
|---|---|
| instanceOf |
checkpoint inhibitor
ⓘ
immunotherapy ⓘ monoclonal antibody ⓘ pharmaceutical drug ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToPathway |
PD-1/PD-L1 signaling pathway
ⓘ
immune checkpoint pathway ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
endocrinopathies ⓘ fatigue ⓘ immune-related colitis ⓘ immune-related hepatitis ⓘ immune-related pneumonitis ⓘ nausea ⓘ pruritus ⓘ rash ⓘ |
| developedBy | Merck & Co. NERFINISHED ⓘ |
| developerCountry | United States NERFINISHED ⓘ |
| firstFDAApprovalYear | 2014 ⓘ |
| firstIndication | unresectable or metastatic melanoma ⓘ |
| formulation | solution for infusion ⓘ |
| hasATCCode | L01FF02 ⓘ |
| hasCASNumber | 1374853-91-4 ⓘ |
| hasDrugClass | PD-1 inhibitor ⓘ |
| hasGenericName | pembrolizumab ⓘ |
| hasIndicationType |
advanced cancer
ⓘ
metastatic cancer ⓘ unresectable cancer ⓘ |
| hasINN | pembrolizumab NERFINISHED ⓘ |
| hasMoleculeType |
IgG4 kappa antibody
ⓘ
humanized monoclonal antibody ⓘ |
| hasTradeName | Keytruda NERFINISHED ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isPrescriptionDrug | true ⓘ |
| mechanismOfAction |
blocks PD-1 pathway
ⓘ
enhances T-cell mediated immune response against tumors ⓘ |
| routeOfAdministration | intravenous ⓘ |
| targets |
PD-1 receptor
NERFINISHED
ⓘ
programmed cell death protein 1 NERFINISHED ⓘ |
| usedFor |
cancer treatment
ⓘ
cervical cancer ⓘ classical Hodgkin lymphoma NERFINISHED ⓘ endometrial carcinoma ⓘ esophageal cancer ⓘ gastric cancer ⓘ head and neck squamous cell carcinoma ⓘ hepatocellular carcinoma ⓘ melanoma ⓘ microsatellite instability-high cancers ⓘ mismatch repair deficient cancers ⓘ non-small cell lung cancer ⓘ renal cell carcinoma ⓘ triple-negative breast cancer ⓘ urothelial carcinoma ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
pembrolizumab